Geron (NASDAQ:GERN) Trading Down 3% – Time to Sell?

Geron Co. (NASDAQ:GERN)’s share price fell 3% on Monday . The stock traded as low as $1.77 and last traded at $1.77. 1,451,958 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 14,617,280 shares. The stock had previously closed at $1.82.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. HC Wainwright reissued a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. Scotiabank dropped their price objective on Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a report on Thursday, February 27th. B. Riley cut Geron from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $3.50 to $2.00 in a research report on Thursday, February 27th. Finally, Barclays reaffirmed an “overweight” rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.75.

Geron Stock Down 4.5 %

The stock has a 50 day moving average price of $2.42 and a 200 day moving average price of $3.47. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.43 and a beta of 0.53.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. As a group, analysts forecast that Geron Co. will post -0.25 EPS for the current year.

Hedge Funds Weigh In On Geron

A number of hedge funds have recently bought and sold shares of GERN. SBI Securities Co. Ltd. acquired a new position in shares of Geron in the 4th quarter valued at about $28,000. Integrated Wealth Concepts LLC bought a new position in Geron during the fourth quarter worth $36,000. GF Fund Management CO. LTD. acquired a new stake in Geron in the fourth quarter worth $45,000. 111 Capital bought a new stake in Geron in the fourth quarter valued at $52,000. Finally, Fifth Lane Capital LP acquired a new position in shares of Geron during the fourth quarter valued at about $53,000. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.